"I never commit to timelines but I would be very comfortable to say at the very least within this decade," Martin Holst Lange said in an interview.
Novo expects both its new experimental obesity drugs cagrisema and amycretin to have similar cardiac benefits as its wildly popular weight-loss drug Wegovy.
Novo Nordisk hopes to advance the development of amycretin in its oral and injectable form simultaneously, Lange said.
The drugmaker in August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug.
